📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
161 analysed today
FollowTelegram
161
Today
149,562
All-time analysed
42,894
Positive
6,654
Negative
91,341
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
25 announcements match the current filters (relevance ≥ 5).
KRONOX Q1 Results: PAT Grows 14.6% YoY to ₹7.30 Cr; Record Date for Dividend Set
Kronox Lab Sciences reported a steady Q1 FY27 with revenue from operations growing 13.4% YoY to ₹28.31 Cr. Net profit (PAT) increased by 14.6% YoY to ₹7.30 Cr, maintaining a strong PAT margin of approximately 25.8%. The company has scheduled its 17th Annual General Meeting for September 16, 2026, and fixed September 09, 2026, as the record date for determining dividend eligibility. Additionally, the board approved the re-appointment of internal and cost auditors for the 2026-27 fiscal year.
Confidence: HIGH
What changedThe company reported its first-quarter financial performance for FY27 and formalized the timeline for its annual general meeting and dividend record date.
Why it mattersThe results demonstrate the company's ability to maintain high margins (PAT >25%) in the specialty chemicals space, supported by its low debt (₹2 Cr) and high ROCE (36%).
Revenue (Q1 FY27): ₹28.31 CrPAT (Q1 FY27): ₹7.30 CrPAT Margin: 25.78%Record Date: September 09, 2026Debt-to-Equity: 0.02
📅 Short termThe stock may see positive sentiment due to the double-digit growth in both revenue and profit, alongside the upcoming dividend record date.
📈 Long termThe long-term outlook depends on the successful operationalization of Unit-IV at Dahej to scale its high-purity chemical portfolio for the pharmaceutical industry.
⚠ Risk flags
- Slowdown in global pharmaceutical R&D spending
- Potential delays in Unit-IV construction
- Supply chain risks for specialized chemical precursors
Key Highlights
Revenue from operations increased 13.4% YoY to ₹28.31 Cr from ₹24.97 Cr in the previous year's quarter.
Profit After Tax (PAT) rose 14.6% YoY to ₹7.30 Cr compared to ₹6.37 Cr in Q1 FY26.
Earnings Per Share (EPS) improved to ₹1.97 for the quarter, up from ₹1.72 YoY.
Record date for the final dividend and 17th AGM is fixed for September 09, 2026.
Total expenses for the quarter stood at ₹19.87 Cr, with material costs accounting for ₹15.09 Cr.
👀 What to Watch
Investors should monitor the progress of the Unit-IV expansion at Dahej, which is the primary driver for the company's targeted 15-20% growth rate. The upcoming AGM on September 16 will provide further clarity on dividend payouts and future capacity timelines.
₹7.30 Cr PAT: Kronox Lab Sciences Reports 14.6% YoY Profit Growth in Q1 FY27
Kronox Lab Sciences reported a steady Q1 FY27 with revenue from operations growing 13.4% YoY to ₹28.31 Cr. Net profit increased by 14.6% YoY to ₹7.30 Cr, up from ₹6.37 Cr in the corresponding quarter last year. The company maintained strong profitability with a Profit Before Tax (PBT) of ₹9.81 Cr. Additionally, the board has fixed September 9, 2026, as the record date for the 17th Annual General Meeting and dividend entitlement.
Confidence: HIGH
What changedKronox has transitioned into the new fiscal year with positive growth in both revenue and profit while formalizing its annual shareholder meeting and auditor appointments.
Why it mattersThe results demonstrate the company's ability to maintain high margins (PBT margin at ~34.6%) in the specialty fine chemicals segment, supporting its qualitative profile of strong pricing power.
Revenue (Q1 FY27): ₹28.31 CrNet Profit (Q1 FY27): ₹7.30 CrYoY Revenue Growth: 13.4%YoY PAT Growth: 14.6%Record Date: September 09, 2026
📅 Short termThe stock may see positive sentiment in the coming days due to the YoY growth in earnings and the announcement of the AGM/dividend record date.
📈 Long termStructural growth depends on the operationalization of Unit-IV at Dahej to tap into export advantages and the high-purity chemical segment.
⚠ Risk flags
- Dependence on pharmaceutical R&D spending
- Potential delays in Unit-IV construction
- Raw material supply chain risks for specialized precursors
Key Highlights
Revenue from operations increased 13.4% YoY to ₹28.31 Cr from ₹24.97 Cr.
Net profit for the quarter rose 14.6% YoY to ₹7.30 Cr.
Earnings Per Share (EPS) improved to ₹1.97 from ₹1.72 in the year-ago period.
Total income for the quarter stood at ₹29.68 Cr, including other income of ₹1.37 Cr.
Record date for the 17th AGM and final dividend set for September 9, 2026.
👀 What to Watch
Investors should monitor the execution timeline of the Unit-IV expansion at Dahej, which is the primary driver for the company's 15-20% growth target. The upcoming AGM on September 16, 2026, will provide further clarity on dividend payouts.
Kronox Lab Sciences FY26 PAT Rises 8.6% to ₹27.66 Cr; Recommends ₹0.50 Final Dividend
Kronox Lab Sciences reported a steady financial performance for FY26, with annual revenue reaching ₹101.22 crore. The company's net profit for the full year grew by 8.6% to ₹27.66 crore, up from ₹25.46 crore in the previous fiscal. The fourth quarter was particularly strong, with PAT increasing to ₹8.00 crore compared to ₹6.32 crore YoY, despite flat revenue growth in the same period. To reward shareholders, the board has recommended a final dividend of ₹0.50 per equity share.
Key Highlights
Annual Net Profit increased by 8.6% to ₹2,766.00 Lacs in FY26 from ₹2,545.71 Lacs in FY25
Q4 FY26 PAT grew significantly to ₹800.21 Lacs versus ₹631.52 Lacs in the year-ago quarter
Full-year Revenue from Operations stood at ₹10,122.00 Lacs, a marginal increase from ₹10,018.40 Lacs
Board recommended a final dividend of ₹0.50 per equity share (5% of face value)
Earnings Per Share (EPS) for FY26 improved to ₹7.51 from ₹6.81 in FY25
👀 What to Watch
The company shows strong margin improvement and consistent profit growth despite flat revenue, making it a positive hold for long-term investors. Monitor the upcoming AGM for dividend approval and management's outlook on future revenue scaling.
Kronox Lab Sciences FY26 Net Profit Rises 8.6% to ₹27.66 Cr; Declares ₹0.50 Dividend
Kronox Lab Sciences reported a steady financial performance for the fiscal year ended March 31, 2026, with annual revenue from operations reaching ₹101.22 crore. Net profit for the year grew to ₹27.66 crore, up from ₹25.46 crore in the previous fiscal year, reflecting improved margins. The company's board has recommended a final dividend of ₹0.50 per equity share (5% of face value). Earnings per share (EPS) improved to ₹7.51 from ₹6.81 YoY, indicating consistent value creation for shareholders.
Key Highlights
Annual Revenue from Operations grew to ₹101.22 crore in FY26 compared to ₹100.18 crore in FY25.
Net Profit (PAT) for the full year increased by 8.6% YoY to ₹27.66 crore.
Board recommended a final dividend of ₹0.50 per equity share of face value ₹10.
Q4 FY26 standalone PAT stood at ₹8.00 crore, showing growth over the ₹6.32 crore reported in Q4 FY25.
The company maintains a strong balance sheet with total equity increasing to ₹116.13 crore from ₹90.11 crore.
👀 What to Watch
Investors should note the steady profit growth and dividend payout; however, the marginal revenue growth suggests a need to monitor future top-line expansion strategies.
Kronox Lab Sciences Q3 FY26 PAT at ₹6.59 Cr; Revenue Grows 5.2% YoY to ₹25.27 Cr
Kronox Lab Sciences reported a steady but modest performance for the quarter ended December 31, 2025, with revenue from operations growing 5.2% YoY to ₹25.27 crore. Net profit for the quarter stood at ₹6.59 crore, showing a marginal increase from ₹6.53 crore in the same period last year. On a sequential basis, both revenue and profit saw a slight dip compared to the September 2025 quarter. For the nine-month period, the company maintained stability with a PAT of ₹19.66 crore compared to ₹19.15 crore in the previous year.
Key Highlights
Revenue from operations increased to ₹2,527.40 lakhs in Q3 FY26 from ₹2,401.11 lakhs in Q3 FY25.
Net Profit (PAT) for the quarter recorded at ₹658.90 lakhs, up marginally from ₹652.86 lakhs YoY.
Total expenses for the quarter rose to ₹1,780.85 lakhs compared to ₹1,600.35 lakhs in the previous year's quarter.
Nine-month (9M FY26) PAT reached ₹1,965.79 lakhs, representing a 2.6% growth over 9M FY25.
Basic and Diluted Earnings Per Share (EPS) for the quarter stood at ₹1.78, compared to ₹1.77 in the year-ago period.
👀 What to Watch
The results indicate stable but slow growth with rising expenses impacting margins. Investors should maintain a hold position while monitoring the company's ability to scale revenue in the specialty chemicals segment.
